News

Sarepta Makes Big Cuts After Patient Deaths. Its Prospects Remain Uncertain.
The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene ...
Sarepta: Safety And Efficacy Flaws Undermine Gains On Restructuring News
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Sarepta Therapeutics: What's Happening With SRPT Stock?
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
STAT4h
Inside an FDA drug rejection, and layoffs at Sarepta
Just how many employees is Sarepta Therapeutics laying off? And why did the FDA reject Ultragenyx's rare disease drug over ...
BioSpace10h
Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic
Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...
Sarepta: Finally, A Little Relief For Bulls; I Expect More
Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...
GEN - Genetic Engineering and Biotechnology News21h
Sarepta Axes 500, 36% of Workforce, in Restructuring after DMD Patient Deaths
Sarepta Therapeutics said it will eliminate 36% of its workforce—approximately 500 jobs—in a restructuring that follows the ...
These Stocks Are Moving the Most Today: Lucid, TSMC, Elevance, Sarepta, PepsiCo, Abbott Labs, Archer Daniels, and More
Lucid soars after announcing a self-driving partnership with Uber Technologies and Nuro, Taiwan Semiconductor Manufacturing ...